Kymera Therapeutics, Inc. (NASDAQ:KYMR) Short Interest Up 8.8% in March

Kymera Therapeutics, Inc. (NASDAQ:KYMR) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totalling 9,060,000 shares, a growth of 8.8% from the March 15th total of 8,330,000 shares. Based on an average daily trading volume, of 752,000 shares, the short-interest ratio is presently 12.0 days.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Kymera Therapeutics in a research report on Thursday, February 15th. They issued a “peer perform” rating for the company. Truist Financial lifted their target price on shares of Kymera Therapeutics from $41.00 to $54.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Piper Sandler lifted their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the stock an “overweight” rating in a report on Tuesday, February 27th. Wells Fargo & Company downgraded shares of Kymera Therapeutics from an “overweight” rating to an “equal weight” rating and set a $26.00 target price for the company. in a report on Tuesday, December 19th. Finally, Stifel Nicolaus lifted their target price on shares of Kymera Therapeutics from $35.00 to $55.00 and gave the stock a “buy” rating in a report on Friday, February 23rd. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $39.89.

Kymera Therapeutics Stock Performance

Shares of NASDAQ:KYMR opened at $33.93 on Wednesday. The firm has a 50 day moving average of $39.20 and a 200-day moving average of $27.64. Kymera Therapeutics has a 12 month low of $9.60 and a 12 month high of $45.31.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Thursday, February 22nd. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.19. The company had revenue of $47.90 million during the quarter, compared to analysts’ expectations of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. The business’s revenue for the quarter was up 197.5% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.60) EPS. As a group, equities research analysts predict that Kymera Therapeutics will post -3.13 earnings per share for the current fiscal year.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 51,184 shares of Kymera Therapeutics stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $2,193,234.40. Following the sale, the director now directly owns 881,266 shares in the company, valued at approximately $37,762,248.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Jeffrey W. Albers sold 10,000 shares of Kymera Therapeutics stock in a transaction dated Tuesday, January 23rd. The shares were sold at an average price of $30.05, for a total value of $300,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bruce Booth sold 51,184 shares of Kymera Therapeutics stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $2,193,234.40. Following the completion of the transaction, the director now directly owns 881,266 shares of the company’s stock, valued at approximately $37,762,248.10. The disclosure for this sale can be found here. In the last three months, insiders have sold 484,051 shares of company stock worth $19,924,711. Insiders own 16.67% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd acquired a new position in Kymera Therapeutics during the 1st quarter worth approximately $53,000. Amundi acquired a new position in Kymera Therapeutics during the 4th quarter worth approximately $49,000. Advisors Asset Management Inc. acquired a new position in Kymera Therapeutics during the 4th quarter worth approximately $58,000. Royal Bank of Canada grew its holdings in Kymera Therapeutics by 30.0% during the 2nd quarter. Royal Bank of Canada now owns 2,773 shares of the company’s stock worth $64,000 after acquiring an additional 640 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Kymera Therapeutics by 65.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,899 shares of the company’s stock worth $67,000 after acquiring an additional 1,146 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.